Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics


Aeterna Zentaris Inc. (AEZS)

Today's Latest Price: $0.77 USD

0.02 (3.21%)

Updated Jan 28 10:11am

Add AEZS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

AEZS Stock Summary

  • AEZS has a higher market value than only 3.89% of US stocks; more precisely, its current market capitalization is $14,995,882.
  • Aeterna Zentaris Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.61% of US listed stocks.
  • AEZS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 0.27% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Aeterna Zentaris Inc, a group of peers worth examining would be APEN, REKR, AVCT, AZUL, and HRB.
  • Visit AEZS's SEC page to see the company's official filings. To visit the company's web site, go to www.zentaris.com.

AEZS Stock Price Chart Interactive Chart >

Price chart for AEZS

AEZS Price/Volume Stats

Current price $0.77 52-week high $1.38
Prev. close $0.75 52-week low $0.29
Day low $0.75 Volume 10,299,711
Day high $0.82 Avg. volume 12,745,346
50-day MA $0.49 Dividend yield N/A
200-day MA $0.58 Market Cap 48.52M

Aeterna Zentaris Inc. (AEZS) Company Bio


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.


AEZS Latest News Stream


Event/Time News Detail
Loading, please wait...

AEZS Latest Social Stream


Loading social stream, please wait...

View Full AEZS Social Stream

Latest AEZS News From Around the Web

Below are the latest news stories about Aeterna Zentaris Inc that investors may wish to consider to help them evaluate AEZS as an investment opportunity.

Aeterna Zentaris jumps on additional time to regain listing compliance

Aeterna Zentaris ([[AEZS]] +6.8%) received a notification letter from Nasdaq Stock Market notifying the Company that it has been granted an additional 180 calendar day period until July 26, 2021 to regain compliance with the minimum bid price requirement for continued listing.The company received share price deficiency from Nasdaq last year in July until...

Seeking Alpha | January 27, 2021

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

CHARLESTON, S.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has been granted an additional 180 calendar day period to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's shares, which will continue to trade on the Nasdaq Capital Market under the symbol “AEZS”. The Company has an additional 180 calendar da...

Yahoo | January 26, 2021

Aeterna Zentaris to Present at NobleCon17

– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET –CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at NobleCon17 - Noble Capital Markets’ Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 12:00 PM ET.A high-definition, video webcast will be available at the time of the Company’s presentation to those registered to attend the event. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com.A webcast replay will be available ap...

Yahoo | January 15, 2021

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical…

GlobeNewswire | January 5, 2021

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive licensing agreement (the “Agreement”) with Consilient Health, Ltd. (“CH” or “Consilient Health”), a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East, for the commercialization in Europe and the United Kingdom of macimorelin, Aeterna’s orally available ghrelin agonist, in any diagnostic application, including the diagnosis of patients with adult growth hormone deficiency (“AGHD”) and, subject to receipt of regulato...

Yahoo | December 7, 2020

Read More 'AEZS' Stories Here

AEZS Price Returns

1-mo 91.40%
3-mo 146.40%
6-mo 64.00%
1-year -34.75%
3-year -67.23%
5-year -76.31%
YTD 80.96%
2020 -53.24%
2019 -69.05%
2018 24.58%
2017 -34.44%
2016 -19.64%

Continue Researching AEZS

Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:

Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8165 seconds.